# Jubilant Innovation Pte Ltd Balance Sheet as at 31 March 2019

balance Sheet as at 51 March 2019		USD	INR (' In Thousands)	USD	INR (' In Thousands)
	Notes		As at		As at
	110105		31 March 2019		31 March 2018
ASSETS					
Non-current assets					
Financial assets					
i. Non-current investments	1	480,536	33,234	480,536	31,317
ii. Loans	2	3,994	276	3,994	260
Total non-current assets		484,530	33,510	484,530	31,577
Current assets					
Financial assets					
i. Cash and cash equivalents	3	7,004	484	943	61
Other current assets	4	4,749	329	2,674	174
Total current assets		11,753	813	3,617	235
Total assets	_	496,283	34,323	488,147	31,812
EQUITY AND LIABILITIES					
Equity					
Equity share capital	5	2,922,301	138,091	2,922,301	138,091
Other equity		(2,514,110)	(109,861)	(2,490,149)	(109,928)
Total Equity	_	408,191	28,230	432,152	28,163
LIABILITIES					
Non-current liabilities					
Financial liabilities					
i. Borrowings	6	30,000	2,074	20,000	1,303
Total non-current liability	_	30,000	2,074	20,000	1,303
Current liabilities					
Financial liabilities					
i. Trade payables	7	56,478	3,907	35,368	2,305
i. Other financial liability	8	1,614	112	627	41
Total current liabilities		58,092	4,019	35,995	2,346
Total liabilities		88,092	6,093	55,995	3,649
Total equity and liabilities		496,283	34,323	488,147	31,812

Benny Thomas General Manager Finance

### Jubilant Innovation Pte Ltd Statement of Profit and Loss for the year ended 31 March 2019

Statement of Front and Loss for the year ended 51 War		USD	INR (' In Thousands)	USD	INR (' In Thousands)
	Notes		the year ended 31 March 2019		the year ended 31 March 2018
Revenue from operations		-	-	-	-
Total income		-	-	-	-
Expenses					
Finance costs	9	986	70	627	40
Other expenses	10	22,975	1,618	26,692	1,719
Total expenses		23,961	1,688	27,319	1,759
Loss before tax		(23,961)	(1,688)	(27,319)	(1,759)
Tax expense					
- Current tax		-	-	-	-
Total tax expense		-	-	-	-
Loss for the year		(23,961)	(1,688)	(27,319)	(1,759)
Other comprehensive income					
Items that will not be reclassified to profit or loss					
Exchange differences on translation of foreign operations		-	1,755	-	97
Other comprehensive income for the year, net of tax		-	1,755	-	97
Total comprehensive (loss)/income for the year		(23,961)	67	(27,319)	(1,662)

Benny Thomas General Manager Finance

#### Jubilant Innovation Pte Ltd Statement of Change in Equity for the year ended 31 March 2019

# A. Equity Share Capital

2,922,301
-
2,922,301
-
2,922,301

### **B.** Other Equity

		USD
	Reserves and Surplus	Total
	<b>Retained</b> earnings	
Balance as at 1 April 2017	(2,410,226)	(2,410,226)
Loss for the year	(27,319)	(27,319)
Total comprehensive loss for the year	(27,319)	(27,319)
Investment transferred to holding company	(52,604)	(52,604)
Balance as at 31 March 2018	(2,490,149)	(2,490,149)
Balance as at 1 April 2018	(2,490,149)	(2,490,149)
Loss for the year	(23,961)	(23,961)
Total comprehensive loss for the year	(23,961)	(23,961)
Balance as at 31 March 2019	(2,514,110)	(2,514,110)

Benny Thomas General Manager Finance

Statement of Change in Equity for the year ended 31 March 2019

# A. Equity Share Capital

	INR (' In
	Thousands)
Balance as at 1 April 2017	138,091
Additions during the year	-
Balance as at 31 March 2018	138,091
Additions during the year	-
Balance as at 31 March 2019	138,091

# **B.** Other Equity

			INR (' In Thousands)
	Reserves and Surplus	Other Comprehensive Income	Total
	Retained earnings	Foreign currency translation reserve	
Balance as at 1 April 2017	(106,230)	1,347	(104,883)
Loss for the year	(1,759)		(1,759)
Other comprehensive income of the year		97	97
Total comprehensive loss for the year	(1,759)	97	(1,662)
Investment transferred to holding company	(3,383)		(3,383)
Balance as at 31 March 2018	(111,372)	1,444	(109,928)
Balance as at 1 April 2018	(111,372)	1,444	(109,928)
Loss for the year	(1,688)		(1,688)
Other comprehensive income of the year		1,755	1,755
Total comprehensive income/( loss) for the year	(1,688)	1,755	67
Balance as at 31 March 2019	(113,060)	3,199	(109,861)

Benny Thomas General Manager Finance

Statement of Cash Flows for the year ended 31 March 2019	

·	USD	INR (' In Thousands)	USD	INR (' In Thousands)
	For the year ended 31 March 2019		For the year ended 31 March 2018	
A. Cash flow from operating activities				
Loss before tax	(23,961)	(1,688)	(27,319)	(1,759)
Adjustments:				
Finance costs	986	70	627	40
Operating cash flow before working capital changes	(22,975)	(1,618)	(26,692)	(1,719)
(Increase)/decrease in trade and other receivables	(2,075)	(146)	728	47
Increase in trade payables, provisions and other liabilities	21,111	1,487	7,280	470
Cash used in operations	(3,939)	(278)	(18,684)	(1,202)
Net cash used in operating activities	(3,939)	(278)	(18,684)	(1,202)
B. Cash flow arising from financing activities				
Proceeds from borrowings	10,000	705	20,000	1,291
Net cash generated from financing activities	10,000	705	20,000	1,291
C. Effect of exchange rate changes	-	(4)	-	(4)
Net increase in cash and cash equivalents (A+B+C)	6,061	423	1,316	85
Add: cash and cash equivalents at the beginning of year	943	61	(373)	(24)
Cash and cash equivalents at the end of the year	7,004	484	943	61

Benny Thomas General Manager Finance

### Notes to the financial statements for the year ended 31 March 2019

#### Note 1: Non-current Investment

	USD	INR (' In Thousands)	USD	INR (' In Thousands)
		As at		As at
		31 March 2019		31 March 2018
Non-current				
Vanthys Pharmaceuticals Development Private Limited (net of	480,536	33,234	480,536	31,317
provision for impairment)				
22,500,000 (31 March 2018: 22,500,000 shares of Rs 10 each)				
Total non-current investment	480,536	33,234	480,536	31,317
Note 2: Loans				
	USD	INR (' In	USD	INR (' In
		Thousands)		Thousands)
		As at		As at
		31 March 2019		31 March 2018
Non-current				
Unsecured, considered good				
Security deposits	3,994	276	3,994	260
Total loans and advances	3,994	276	3,994	260
Note 3: Cash and cash equivalents				
	USD	INR (' In	USD	INR (' In
		Thousands)		Thousands)
		As at		As at
		31 March 2019		31 March 2018
Balances with banks				
- in current accounts	7,004	484	943	61
Total cash and cash equivalents	7,004	484	943	61
Note 4: Other current assets				
	USD	INR (' In	USD	INR (' In
		Thousands)		Thousands)
		As at		As at
		31 March 2019		31 March 2018
Prepaid expenses	4,749	328	2,674	174
Total other current assets	4,749	328	2,674	174

Notes to the financial statements for the year ended 31 March 2019

Note 5: Share Capital				
	USD	INR (' In	USD	INR (' In
		Thousands)		Thousands)
		As at		As at
		31 March 2019		31 March 2018
Issued, subscribed and paid up				
2,922,301 (31 March 2018: 2,922,301 Equity shares at no par value)	2,922,301	138,091	2,922,301	138,091

1) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share.

2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.3) The details of shareholders holding more than 5% shares in the Company:

		As at		As at
		31 March 2019		31 March 2018
	No of shares	% holding in the class	No of shares	% holding in the class
Name of the Shareholder				
Drug Discovery and Development Solutions Limited	2,922,301	100%	2,922,301	100%
4) The reconciliation of the number of shares outstanding as at beginning and	at end of the reporting period	od		
		As at		As at
		31 March 2019		31 March 2018
	No of shares	USD	No of shares	USD
Numbers of shares at the beginning	2,922,301	2,922,301	2,922,301	2,922,301
Add: Shares issued during the year	-	-	-	-
Number of shares at the end	2,922,301	2,922,301	2,922,301	2,922,301
		As at		As at
		31 March 2019		31 March 2018
	No of shares	INR (' In	No of shares	INR (' In
		Thousands)		Thousands)
Numbers of shares at the beginning	2,922,301	138,091	2,922,301	138,091
	-	-	-	-
Add: Shares issued during the year				138,091

As at 31 March 2018

> % holding 100%

b) Shares here by horang company, animate horang company are as given berow.			
		As at	t
		31 March 2019	)
NT	. Cl	0/ 1-112	N C.C.

	No of Shares	% holding	No of Shares
Drug Discovery and Development Solutions Limited	2,922,301	100%	2,922,301

Notes to the financial statements for the year ended 31 March 2019

Note 6: Borrowings

Tote 0. Dorrowings	USD	INR (' In Thousands)	USD	INR (' In Thousands)	
		As at 31 March 2019		As at 31 March 2018	
Non-current					
Loan from related parties	30,000	2,074	20,000	1,303	
Total Borrowings	30,000	2,074	20,000	1,303	
Note 7: Trade payables					
	USD	INR (' In	USD	INR (' In	
		Thousands)		Thousands)	
		As at 31 March 2019		As at 31 March 2018	
Current					
Trade payables	56,478	3,907	35,368	2,305	
Total trade payables	56,478	3,907	35,368	2,305	
Note 8: Other Financial Liability					
	USD	INR (' In	USD	INR (' In	
		Thousands)		Thousands)	
		As at		As at	
		31 March 2019		31 March 2018	
Current					
Interest accrued on loan from related parties	1,614	111	627	41	
Total other financial liability	1,614	111	627	41	
Note 9: Finance cost					
	USD	INR (' In	USD	INR (' In	
		Thousands)		Thousands)	
articulars		As at		As at	
		31 March 2019		31 March 2018	
Interest expense	986	70	627	40	
Total Finance costs	986	70	627	40	
Note 10: Other expenses					
	USD	INR (' In Thousands)	USD	INR (' In Thousands)	
Particulars	For	For the year ended		For the year ended	
		31 March 2019		31 March 2018	
Auditors remuneration	6,202	437	6,330	407	
Legal and professional fees	14,244	1003	17328	1116	
Bank charges	2,529	178	2447	158	
Subscription	-	-	321	21	
Foreign exchange loss	-	-	266	17	